CN107692087A - 一种辅助降压的海参肠保健食品 - Google Patents
一种辅助降压的海参肠保健食品 Download PDFInfo
- Publication number
- CN107692087A CN107692087A CN201610643674.2A CN201610643674A CN107692087A CN 107692087 A CN107692087 A CN 107692087A CN 201610643674 A CN201610643674 A CN 201610643674A CN 107692087 A CN107692087 A CN 107692087A
- Authority
- CN
- China
- Prior art keywords
- sea cucumber
- parts
- health food
- powder
- rice noodle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251511 Holothuroidea Species 0.000 title claims abstract description 91
- 210000000936 intestine Anatomy 0.000 title claims abstract description 51
- 235000013402 health food Nutrition 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 21
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 19
- 235000012149 noodles Nutrition 0.000 claims abstract description 19
- 235000009566 rice Nutrition 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 9
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 9
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 9
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 8
- 240000007594 Oryza sativa Species 0.000 claims abstract 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 238000000746 purification Methods 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 230000009849 deactivation Effects 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006000 Garlic extract Substances 0.000 claims 1
- 235000020706 garlic extract Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 14
- 240000002234 Allium sativum Species 0.000 abstract description 8
- 235000004611 garlic Nutrition 0.000 abstract description 8
- 230000036772 blood pressure Effects 0.000 abstract description 7
- 230000000050 nutritive effect Effects 0.000 abstract description 5
- 230000011132 hemopoiesis Effects 0.000 abstract description 3
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 230000002929 anti-fatigue Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 241000209094 Oryza Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 241001092040 Crataegus Species 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000965254 Apostichopus japonicus Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QXNWZXMBUKUYMD-ITUXNECMSA-N 4-keto-beta-carotene Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C QXNWZXMBUKUYMD-ITUXNECMSA-N 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 2
- 235000010591 Appio Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 2
- -1 carrotene Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001526627 Azumapecten farreri Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 229930188089 Holothurin Natural products 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241001212699 Pinctada martensii Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241001441726 Tetraodontiformes Species 0.000 description 1
- 241001222097 Xenocypris argentea Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- YXPMCBGFLULSGQ-YHEDCBSUSA-N echinenone Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(=O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C YXPMCBGFLULSGQ-YHEDCBSUSA-N 0.000 description 1
- 235000006932 echinenone Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- MAWWITJOQDJRJF-ADBICINLSA-M holothurin Chemical compound [Na+].O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H](OC[C@H]([C@@H]3O)OS([O-])(=O)=O)O[C@@H]3C([C@H]4[C@](C=5[C@H]([C@@]6(CC[C@]7(O)[C@](C)([C@H]8OC(C)(C)CC8)OC(=O)[C@@]76[C@@H](O)C=5)C)CC4)(C)CC3)(C)C)O[C@@H]2C)O)O[C@H](C)[C@H]1O MAWWITJOQDJRJF-ADBICINLSA-M 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种含有海参肠粉的辅助降低血压血脂的保健食品,包括以下重量份数组成:海参肠粉3‑15份、芹菜粉20‑30份、山楂粉30‑40份、葛根粉10‑20份、银杏叶提取物5‑10份、大蒜提取物5‑12份、微晶纤维素1‑3份。本发明保健食品是首次使用具有抗疲劳增强抵抗力,促进造血功能的海参肠粉配以具有明显降压作用的芹菜粉,山楂粉,葛根粉,银杏叶提取物,大蒜提取物等药食同源的成分加工成保健食品,可以明显的增强患者体质,增强抵抗力,降低血压,减轻患者对降压药的依赖。海参肠同海参一样具有较高的营养保健价值,海参肠粉价格低廉,本发明大大降低了消费者的经济负担。
Description
技术领域
本发明涉及一种保健食品,具体是一种含有海参肠粉的辅助降血压的保健食品。
背景技术
高血压是最常见的心血管疾病,是目前全球范围内的重大公共卫生问题。根据世界卫生组织预测,至2020年,非传染性疾病将占我国死亡原因的79%,其中心血管病将占首位,因此,高血压疾病的预防和治疗工作尤为重要。
为了控制血压偏高的状况,高血压患者要长期服用药物,不论是中药还是西药,都有各自的优缺点。 西药注重病理,一旦停药血压很快反弹;中药降压效果较差,但注重机理的调节。
化学合成的抗高血压药物在高血压治疗中的作用得到了医学界的普遍认可,但其存在对人体的副作用。
患者们更希望寻求一种非化学合成药来达到降压的目的,因此辅助降压保健食品的诞生正符合人们对健康的需求。
有研究证明高血压等症状与人的体质有关,单纯靠化学药物强行降压,不改变体质,早晚成为药罐子、病秧子。由此降血压保健食品的目的不单纯是降低血压,更应注重调理机体阴阳平衡,促进心、脑、肾、血管病理改变的恢复,增强身体素质,提高身体的抵抗力。
而目前市场上的降压降脂的保健品品种繁多,但能集治疗、滋养为一体的保健品却不多见,尤其目前针对人数众多的弱体质、亚健康人群和高血压患者的保健品更是少之又少,市场上非常缺乏一种能同时起到治疗、滋养弱体质、亚健康人群和高血压病患者的保健品。
海参属于珍贵海味之一,传统习惯上把海参视为滋补食品。经科学验证,海参体内含 50 多种对人体生理活动有益的营养成分,其能够延续人体衰老,补肾益气,强精健髓,消除疲劳的能力,更具有抗凝血、抗肿瘤、抗菌、抗病毒及提高免疫力等作用。海参肠即海参肠衣与海参卵,据研究发现,海参肠中所含有的营养成分,不亚于体壁。但是,目前海参肠一般废弃处理,利用率很低,既浪费了资源又污染了环境。更未见到有使用海参肠来生产具有滋补和降血压双重功效的保健品。
发明内容
本发明涉及一种含有海参肠粉的辅助降低血压血脂的保健食品,以解决技术背景中提出的问题。
本发明采用的技术方案是:其原辅料的重量份数为:
海参肠粉3-15份、
芹菜粉20-30份、
山楂粉30-40份、
葛根粉10-20份、
银杏叶提取物5-10份、
大蒜提取物5-12份、
微晶纤维素1-3份。
进一步的,所述的海参肠粉是采用以下两种方式之一制备:
(1)海参在净化池中通过吐沙净化后捕捞取肠,每份清洗后的海参肠加入0.2-3倍洁净水,加入海参肠重量的0.1%-0.5%的碱性蛋白酶和0.1%-0.5%的风味蛋白酶,在50℃-60℃的温度下进行酶解,酶解0.5-4小时候升温到80-100度灭酶10-30分钟,经过滤、喷雾干燥制得海参肠粉;
(2)海参在净化池中通过吐沙净化后捕捞取肠,然后将海参肠清洗沥干后进行冷冻干燥,干燥后的海参肠再经超微粉碎 200-400目得到粉末。
作为本发明的进一步方案:所述各组分按各自配方量,制成片剂。
作为本发明的进一步方案:所述各组分按各自配方量,制成硬胶囊剂。
作为本发明的进一步方案:所述各组分按各自配方量,制成粉冲剂或丸剂。
本发明的主要功效是:海参属于珍贵海味之一海参属于珍贵海味之一,传统习惯上把海参视为滋补食品。经科学验证,海参体内含 50 多种对人体生理活动有益的营养成分,其能够延续人体衰老,补肾益气,强精健髓,消除疲劳的能力,更具有抗凝血、抗肿瘤、抗菌、抗病毒及提高免疫力等作用。海参肠(消化道)即海参肠衣与海参卵,据研究发现,海参肠中所含有的营养成分,不亚于体壁。
海参肠(内脏,消化道)中含有的氨基酸种类齐全,包含人体必需的 8种氨基酸。其中,游离氨基酸中亮氨酸的含量较高,亮氨酸可纠正由于肝功能衰竭引起的氨基酸紊乱;结合氨基酸中谷氨酸的含量较高。海参肠中必需氨基酸含量分别占氨基酸总量的36.68%,高于海参壁(31.02%),与非必需氨基酸量的比值为0.59,高于海参壁(0.45)。赖氨酸作为第一限制性氨基酸在8种必需氨基酸中含量最高,且高于体壁。海参肠的氨基酸组成与WHO (世界卫生组织 )和 FAO (联合国粮食及农业组织 )提出的 E (必需氨基酸 ) /T (总氨基酸)应为 0.4、E /N (非必需氨基酸 )应为 0.6的蛋白质参考模式接近,而且还含有占氨基酸总量46.86%的药效氨基酸。此外,海参肠壁中还含有体壁没有的牛磺酸,其含量高于牡蛎肉、马氏珠母贝肉中牛磺酸的含量,牛磺酸是一种带有磺酸基的特殊的条件必需氨基酸,它以游离状态富含于兴奋组织(神经、肌肉) 细胞内,对糖尿病病人的神经病变、胰岛素抵抗及心血管并发症具有显著防治作用。这说明海参肠在医学和营养学上都有很高的研究价值,具有开发成保健品或药剂的潜力。
海参肠中脂肪含量比较低,但脂肪酸含量比较高,脂肪酸与粗脂肪的比例为0.43,高于海参体壁(0.42)。 这也可能就是海参有这么高的营养和药用价值的原因之一。
海参肠中脂肪酸有 21种,不饱和脂肪酸占了70%,明显高于体壁中不饱和脂肪酸的含量( 54.2% ),更高于多不饱和脂肪酸含量较高的南极磷虾(47.98% )、黄鳍河豚(37.91% )、三文鱼、栉孔扇贝等。其中二十二碳四烯酸 (C22∶4)和 DHA (C22:6)是海参体壁中所没有的,总量为 5.782 mg/g (湿重)。不饱和脂肪酸 17种,总量4.798 mg/g(湿重)。饱和脂肪酸的种类与海参体壁中的相同。多不饱和脂肪酸中EPA含量最高,占全部脂肪酸的17.36%,同时含有DHA。EPA和 DHA是人体必需的ω-3多不饱和脂肪酸,具有广泛的生理活性,能竞争性地抑制血小板的聚集,减少血栓的形成,预防心脑血管梗塞。因此从脂肪酸的组成和含量来说,海参肠的营养价值比海参体壁还高。
海参肠中含有丰富的海参多糖。海参多糖具有多种药理学作用,如抗氧化:在测定海参肠中多糖及酯化多糖清除羟自由基和超氧阴离子自由基能力时发现,肠壁多糖表现出了一定的抗氧化能力,其清除羟自由基能力以及超氧阴离子自由基的能力大于体壁多糖;抗肿瘤:仿刺参肠多糖对H22肿瘤具有剂量依赖性的抑制作用,且高剂量组(400mg/kg/d)肿瘤抑制效果最好;降血脂:对喂养了五周肠壁多糖的小鼠眼球取血,测定其血清中甘油三酯、低密度脂蛋白胆固醇、总的胆固醇、高密度脂蛋白胆固醇的含量,结果表明高中低剂量均能很显著的降低高脂血症小鼠的甘油三酯、低密度脂蛋白胆固醇、总胆固醇的水平,提高动脉硬化指数以及高密度脂蛋白胆固醇值,显示海参肠多糖具有降血脂作用。
海参皂苷,又称海参素,是海参的主要次生代谢产物,肠壁中皂苷含量约为其湿重的1.03%,明显高于体壁皂苷(0.37%)。皂苷均具有溶血能力。此外,海参肠还含有丰富的β-胡萝卜素、虾青素、海胆紫酮等色素以及钒、核酸等成分。据报道,海参肠具有抗氧化、延缓衰老、维持正常的糖代谢作用、刺激机体的造血功能、促进骨骼的造血能力、抗肿瘤、抗辐射、抗真菌、抗胆碱作用,同时还对胃溃疡及十二指肠溃疡有疗效。但是,目前海参肠一般废弃处理,利用率很低,既浪费了资源又污染了环境。
芹菜以嫩茎、叶供食用和药用,其根也可药用。研究发现,芹菜含有黄酮类物质、多不饱和脂肪酸、矿物元素、丁基苯酞类、萜类、香豆素衍生物、叶绿素、氨基酸和膳食纤维等多种生理活性物质。具有抗菌、抗氧化、抗肿瘤和降血脂等多种药理活性。是辅助治疗高血压病及其并发症的首选之品。对于血管硬化,神经衰弱患者亦有辅助治疗作用。
山楂具有强心、抗心律不齐,扩张冠状动脉血流量,降血脂,降血压,降胆固醇,抗菌止痢,助消化等作用。
葛根无毒、无异味、口感好,在食疗上亦显优势。葛根用于治疗高血压病、颈项强痛、冠心病心绞痛等症有良效,能明显升高红细胞膜脂流动性,降低血液黏度和改善微循环并呈量效关系。
据报道,银杏叶提取物(GBE)含有黄酮类、萜类、酚类等多种活性成分, 仅黄酮类化合物就有 20 种, 且含量较高。其具有降压、增加冠状动脉流量、改善脑循环、抑菌、抗病毒等多种药理作用, 对心血管等疾病具有较好的疗效, 对金黄色葡萄球菌、痢疾杆菌及绿脓杆菌均有抑制作用。银杏叶的提取物已广泛用于食品、化妆品和医疗领域。
大蒜的保健和医疗价值很高,具有抗菌消炎、抗病毒、抗氧化、抑制血栓形成、抗肿瘤、防治动脉硬化、降血脂等多种生物活性功能。
微晶纤维素在制药工业中常用作吸附剂、助悬剂、稀释剂、崩解剂。主要在口服片剂和胶囊中用作稀释剂和粘合剂,不仅可用于湿法制粒也可用于干法直接压片。还有一定的润滑和崩解作用,在片剂制备中非常有用。在食品工业上微晶纤维素可作重要的功能性食品基料---膳食纤维素,是一种理想的保健食品添加剂。
与现有技术相比,本发明的有益效果是:本发明的含海参肠的辅助降压保健品,为海参肠的综合利用提供了一种方法,营养价值高,能够充分发挥其保健功效。本发明的海参肠保健品,是在海参净化吐沙后的基础上进行加工,充分发挥海参肠的营养价值,避免了海参肠中的泥沙,腐殖质对后期加工和营养价值的影响。本发明保健食品是首次使用具有抗疲劳增强抵抗力,促进造血功能的的海参肠粉配以具有明显降压作用的芹菜粉,山楂粉,葛根粉,银杏叶提取物,大蒜提取物等药食同源的成分加工成保健食品,可以明显的增强患者体质,增强抵抗力,降低血压,减轻患者对降压药的依赖。而且海参肠具有和海参相同的功效成分,海参作为传统的滋补品,价格高昂,大多数老百姓消费不起。使用海参肠粉价格要比海参便宜很多,大大降低了患者的经济负担。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
本发明实施例中,一种保健食品,包括以下重量份数组成:海参肠粉3份、芹菜粉20份、山楂粉30份、葛根粉10份、银杏叶提取物5份、大蒜提取物5份、微晶纤维素1份。
如下步骤制得:海参在净化池中通过吐沙净化后捕捞取肠,每份清洗后的海参肠加入0.5倍洁净水,加入海参肠重量的0.2的碱性蛋白酶和0.1%的风味蛋白酶,在55℃-58℃的温度下进行酶解,酶解3小时候升温到90度灭酶20分钟,经过滤、喷雾干燥制得海参肠粉。然后与其它6种原料按各自重量比混合,制粒,包装,即得该保健食品。
实施例2:
本发明实施例中,一种保健食品,包括以下重量份数组成:海参肠粉15份、芹菜粉30份、山楂粉40份、葛根粉20份、银杏叶提取物10份、大蒜提取物12份、微晶纤维素3份。
所述保健食品有如下步骤制得:海参在净化池中通过吐沙净化后捕捞取肠,每份清洗后的海参肠加入1倍洁净水,加入海参肠重量的0.3%的碱性蛋白酶和0.2%的风味蛋白酶,在55℃-58℃的温度下进行酶解,酶解2小时候升温到95度灭酶20分钟,经过滤、喷雾干燥制得海参肠粉。然后与其它6种原料按各自重量比混合,制粒,包装,即得该保健食品。
实施例3:
本发明实施例中,一种保健食品,包括以下重量份数组成:海参肠粉10份、芹菜粉25份、山楂粉35份、葛根粉15份、银杏叶提取物7份、大蒜提取物8份、微晶纤维素2份。
所述保健食品有如下步骤制得:海参在净化池中通过吐沙净化后捕捞取肠,然后将海参肠清洗沥干后进行冷冻干燥,干燥后的海参肠再经超微粉碎 300目得到粉末。然后与其它6种原料按各自重量比混合,制粒,包装,即得该保健食品。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当 将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员 可以理解的其他实施方式。
Claims (5)
1.一种辅助降血压的海参肠保健食品,其特征在于:由以下重量份数的组分制成 :海参肠粉3-15份、芹菜粉20-30份、山楂粉30-40份、葛根粉10-20份、银杏叶提取物5-10份、大蒜提取物5-12份、微晶纤维素1-3份。
2.根据权利要求1所述的保健食品,其特征在于,所述的海参肠粉是采用以下两种方式之一制备:
海参在净化池中通过吐沙净化后捕捞取肠,每份清洗后的海参肠加入0.2-3倍洁净水,加入海参肠重量的0.1%-0.5%的碱性蛋白酶和0.1%-0.5%的风味蛋白酶,在50℃-60℃的温度下进行酶解,酶解0.5-4小时候升温到80-100度灭酶10-30分钟,经过滤、喷雾干燥制得海参肠粉;
海参在净化池中通过吐沙净化后捕捞取肠,然后将海参肠清洗沥干后进行冷冻干燥,干燥后的海参肠再经超微粉碎 200-400目得到粉末。
3.根据权利要求 1 所述的保健食品,其特征在于 :所述各组分按各自配方量,制成片剂。
4.根据权利要求 1 所述的保健食品,其特征在于 :所述各组分按各自配方量,制成硬胶囊剂。
5.根据权利要求 1 所述的保健食品,其特征在于 :所述各组分按各自配方量,制成粉冲剂或丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610643674.2A CN107692087A (zh) | 2016-08-09 | 2016-08-09 | 一种辅助降压的海参肠保健食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610643674.2A CN107692087A (zh) | 2016-08-09 | 2016-08-09 | 一种辅助降压的海参肠保健食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107692087A true CN107692087A (zh) | 2018-02-16 |
Family
ID=61168711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610643674.2A Pending CN107692087A (zh) | 2016-08-09 | 2016-08-09 | 一种辅助降压的海参肠保健食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107692087A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109757595A (zh) * | 2019-03-02 | 2019-05-17 | 大连棒棰岛海产股份有限公司 | 海参肠提取物压片糖果及其制法 |
CN110772541A (zh) * | 2018-07-31 | 2020-02-11 | 成都百裕制药股份有限公司 | 预防和/或治疗男性性功能障碍的组合物及其制剂、应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101422205A (zh) * | 2008-10-28 | 2009-05-06 | 山东好当家海洋发展股份有限公司 | 一种海参肠多肽胶囊的制备方法 |
KR20090086495A (ko) * | 2005-12-26 | 2009-08-13 | 소상문 | 해삼 가공제품 및 그 제조방법 |
CN104543669A (zh) * | 2014-12-19 | 2015-04-29 | 渤海大学 | 一种复方海参肠胶囊 |
-
2016
- 2016-08-09 CN CN201610643674.2A patent/CN107692087A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090086495A (ko) * | 2005-12-26 | 2009-08-13 | 소상문 | 해삼 가공제품 및 그 제조방법 |
CN101422205A (zh) * | 2008-10-28 | 2009-05-06 | 山东好当家海洋发展股份有限公司 | 一种海参肠多肽胶囊的制备方法 |
CN104543669A (zh) * | 2014-12-19 | 2015-04-29 | 渤海大学 | 一种复方海参肠胶囊 |
Non-Patent Citations (2)
Title |
---|
李映焕,等: "《安徽中药资源与开发利用》", 30 April 2006, 安徽科学技术出版社 * |
蒋峰: "《新营养健康教育指南:科学营养的观念》", 31 July 2012, 中国医药科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110772541A (zh) * | 2018-07-31 | 2020-02-11 | 成都百裕制药股份有限公司 | 预防和/或治疗男性性功能障碍的组合物及其制剂、应用 |
CN109757595A (zh) * | 2019-03-02 | 2019-05-17 | 大连棒棰岛海产股份有限公司 | 海参肠提取物压片糖果及其制法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106072573A (zh) | 一种适用于老年肌肉衰减症食用的特膳食品 | |
CN104856003A (zh) | 糖尿病非全营养配方食品 | |
US20040076641A1 (en) | Herbal dietary supplement | |
CN104855984A (zh) | 过敏性鼻炎非全营养配方食品 | |
CN104855983A (zh) | 冠心病非全营养配方食品 | |
CN105166545A (zh) | 一种牛配合饲料及其制备方法 | |
CN104855975A (zh) | 肌肉衰减综合征非全营养配方食品 | |
CN101040710A (zh) | 一种内服调节女士内分泌兼外用美容养颜的保健营养冲剂 | |
CN101108227A (zh) | 一种魔芋精粉胶囊 | |
CN104839698A (zh) | 心血管疾病非全营养配方食品 | |
CN104856000A (zh) | 失眠非全营养配方食品 | |
CN104839695A (zh) | 炎性肠病非全营养配方食品 | |
CN104172168A (zh) | 一种调理动脉粥样硬化的方便食品 | |
CN107692087A (zh) | 一种辅助降压的海参肠保健食品 | |
CN108887683A (zh) | 一种药食养生的米饭添加剂及其制备工艺和药食养生米饭 | |
CN104855970A (zh) | 高血压非全营养配方食品 | |
KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
CN104839699A (zh) | 心脏病非全营养配方食品 | |
CN104855969A (zh) | 肝病非全营养配方食品 | |
CN109549206A (zh) | 一种溶栓及预防心血管疾病的功能性食品及其制备方法 | |
CN104855971A (zh) | 骨瘤非全营养配方食品 | |
CN112168869A (zh) | 一种蚁酸中药及其制备方法 | |
CN104921100A (zh) | 调理黄褐斑非全营养配方食品 | |
CN104855999A (zh) | 肾结石非全营养配方食品 | |
CN104855989A (zh) | 脾胃虚寒非全营养配方食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |
|
RJ01 | Rejection of invention patent application after publication |